U.S. Markets close in 1 hr 31 mins
  • S&P 500

    3,629.66
    +52.07 (+1.46%)
     
  • Dow 30

    30,000.45
    +409.18 (+1.38%)
     
  • Nasdaq

    12,015.23
    +134.60 (+1.13%)
     
  • Russell 2000

    1,851.50
    +33.21 (+1.83%)
     
  • Crude Oil

    44.86
    +1.80 (+4.18%)
     
  • Gold

    1,803.00
    -34.80 (-1.89%)
     
  • Silver

    23.25
    -0.39 (-1.64%)
     
  • EUR/USD

    1.1882
    +0.0037 (+0.3089%)
     
  • 10-Yr Bond

    0.8770
    +0.0200 (+2.33%)
     
  • Vix

    21.75
    -0.91 (-4.02%)
     
  • GBP/USD

    1.3356
    +0.0033 (+0.2511%)
     
  • USD/JPY

    104.5550
    +0.0670 (+0.0641%)
     
  • BTC-USD

    19,184.74
    +732.78 (+3.97%)
     
  • CMC Crypto 200

    380.78
    +11.03 (+2.98%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference

AnaptysBio, Inc.
·2 min read

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 2:55 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://wsw.com/webcast/wedbush36/anab/2181318.

A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at www.anaptysbio.com. A replay of the webcast will be available for 90 days following the event.

About AnaptysBio

AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody etokimab, previously referred to as ANB020, for the treatment of chronic rhinosinusitis with nasal polyps, or CRSwNP, and eosinophilic asthma; its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, and palmoplantar pustulosis, or PPP; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (dostarlimab (GSK4057190A)), an anti-TIM-3 antagonist antibody (GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.

Contact:

Dennis Mulroy
AnaptysBio, Inc.
858.732.0201
dmulroy@anaptysbio.com